Akums Drugs and Pharmaceuticals (NSE:AKUMS) Beneish M-Score: -3.41 (As of Jul. 01, 2026)


NSE:AKUMS Akums Drugs and Pharmaceuticals Ltd NSE:AKUMS
39 GF Score
Price ₹630.85
! 7 Warning Signs
View Full Analysis

What is Akums Drugs and Pharmaceuticals Beneish M-Score?

Akums Drugs and Pharmaceuticals NSE:AKUMS +1.24% 39 Beneish M-Score is -3.41 as of Jul. 01, 2026. GuruFocus rates NSE:AKUMS with a GF Score™ of 39/100. The stock has 7 warning signs investors should review. Among 909 Drug Manufacturers companies, Akums Drugs and Pharmaceuticals ranks better than 90.1% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -3.41 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Akums Drugs and Pharmaceuticals's Beneish M-Score or its related term are showing as below:

NSE:AKUMS' s Beneish M-Score Range Over the Past 10 Years
Min: -3.41   Med: -2.82   Max: -2.5
Current: -3.41

During the past 6 years, the highest Beneish M-Score of Akums Drugs and Pharmaceuticals was -2.50. The lowest was -3.41. And the median was -2.82.


Akums Drugs and Pharmaceuticals Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Akums Drugs and Pharmaceuticals's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Akums Drugs and Pharmaceuticals Beneish M-Score Chart

Akums Drugs and Pharmaceuticals Annual Data
Trend Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Beneish M-Score
Get a 7-Day Free Trial 0.00 -2.66 -2.98 -2.50 -3.41

Akums Drugs and Pharmaceuticals Quarterly Data
Mar21 Mar22 Mar23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.50 0.00 0.00 0.00 -3.41

NSE:AKUMS vs ZTS, UTHR: Beneish M-Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Akums Drugs and Pharmaceuticals's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Akums Drugs and Pharmaceuticals Beneish M-Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Akums Drugs and Pharmaceuticals's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Akums Drugs and Pharmaceuticals's Beneish M-Score falls into.


NSE:AKUMS
39GF Score
Akums Drugs and Pharmaceuticals Ltd NSE:AKUMS
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Akums Drugs and Pharmaceuticals Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Akums Drugs and Pharmaceuticals for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.9804+0.528 * 0.9843+0.404 * 0.652+0.892 * 1.0443+0.115 * 1.0431
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1.2008+4.679 * -0.170005-0.327 * 0.9206
=-3.41

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Total Receivables was ₹7,966 Mil.
Revenue was ₹42,513 Mil.
Gross Profit was ₹17,031 Mil.
Total Current Assets was ₹35,599 Mil.
Total Assets was ₹54,470 Mil.
Property, Plant and Equipment(Net PPE) was ₹16,495 Mil.
Depreciation, Depletion and Amortization(DDA) was ₹1,546 Mil.
Selling, General, & Admin. Expense(SGA) was ₹1,286 Mil.
Total Current Liabilities was ₹10,948 Mil.
Long-Term Debt & Capital Lease Obligation was ₹768 Mil.
Net Income was ₹2,552 Mil.
Gross Profit was ₹0 Mil.
Cash Flow from Operations was ₹11,812 Mil.
Total Receivables was ₹7,780 Mil.
Revenue was ₹40,711 Mil.
Gross Profit was ₹16,054 Mil.
Total Current Assets was ₹22,746 Mil.
Total Assets was ₹41,134 Mil.
Property, Plant and Equipment(Net PPE) was ₹15,636 Mil.
Depreciation, Depletion and Amortization(DDA) was ₹1,534 Mil.
Selling, General, & Admin. Expense(SGA) was ₹1,026 Mil.
Total Current Liabilities was ₹8,937 Mil.
Long-Term Debt & Capital Lease Obligation was ₹673 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(7965.64 / 42513.08) / (7780.47 / 40710.93)
=0.187369 / 0.191115
=0.9804

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(16053.56 / 40710.93) / (17030.98 / 42513.08)
=0.39433 / 0.400606
=0.9843

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (35598.58 + 16495.24) / 54469.65) / (1 - (22746.09 + 15636.49) / 41134.42)
=0.043618 / 0.066899
=0.652

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=42513.08 / 40710.93
=1.0443

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(1534.46 / (1534.46 + 15636.49)) / (1545.51 / (1545.51 + 16495.24))
=0.089364 / 0.085668
=1.0431

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(1286.23 / 42513.08) / (1025.74 / 40710.93)
=0.030255 / 0.025196
=1.2008

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((768.44 + 10947.57) / 54469.65) / ((673.27 + 8937.47) / 41134.42)
=0.215092 / 0.233642
=0.9206

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(2551.88 - 0 - 11812.02) / 54469.65
=-0.170005

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Akums Drugs and Pharmaceuticals has a M-score of -3.41 suggests that the company is unlikely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -3.41 mean?
Akums Drugs and Pharmaceuticals (NSE:AKUMS) has a Beneish M-Score of -3.41 as of Jul. 01, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Akums Drugs and Pharmaceuticals and its competitors. According to the industry distribution chart, Akums Drugs and Pharmaceuticals ranks #90 out of 909 companies in the Drug Manufacturers industry, placing it in the top 9.9%.
Is Akums Drugs and Pharmaceuticals' Beneish M-Score too high?
Akums Drugs and Pharmaceuticals' current Beneish M-Score is -3.41. Based on the distribution chart, Akums Drugs and Pharmaceuticals ranks #90 out of 909 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Akums Drugs and Pharmaceuticals has a GF Score™ of 39/100, reflecting its overall financial health beyond just this single metric.
How does Akums Drugs and Pharmaceuticals' Beneish M-Score compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Akums Drugs and Pharmaceuticals ranks #90 out of 909 companies for Beneish M-Score. This places Akums Drugs and Pharmaceuticals in the top 10% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Drug Manufacturers company?
A good Beneish M-Score depends on the Drug Manufacturers industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Akums Drugs and Pharmaceuticals and its competitors. Akums Drugs and Pharmaceuticals's current Beneish M-Score is -3.41. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Akums Drugs and Pharmaceuticals stock overvalued right now?
Akums Drugs and Pharmaceuticals (NSE:AKUMS) has a current Beneish M-Score of -3.41. The current Beneish M-Score is -3.41. Akums Drugs and Pharmaceuticals' overall GF Score™ is 39/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Akums Drugs and Pharmaceuticals (NSE:AKUMS), the current Beneish M-Score is -3.41 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Akums Drugs and Pharmaceuticals Business Description

Other Exchanges 544222:India
Address Akums House, Plot No. 131 to 133, Block C, Mangolpuri Industrial Area Phase1, Adjoining CBSE Office, Delhi, IND, 110083
Akums Drugs and Pharmaceuticals Ltd a pharmaceutical contract development and manufacturing organization offering a comprehensive range of pharmaceutical products and services in India and overseas. Its services include formulation research and development (R&D), preparation and filing of regulatory dossiers in the Indian and Outside markets, and other testing services. It is also engaged in the manufacturing and sale of branded pharmaceutical formulations and active pharmaceutical ingredients (APIs). It operates in five segments: Contract Development and Manufacturing Operations, Active Pharmaceutical Ingredient (API), Domestic Branded formulations, International Branded Formulations, and Trade generics. Key revenue is generated from Contract Development and Manufacturing Operations.
39GF Score

Get the complete analysis for NSE:AKUMS

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹630.85
Price